There are 349 papers on vasomotor symptoms in aging research: 50 trials and 82 observational studies in people, 7 in animals, 188 reviews.
349 papers study it280 more mention it89 findings
52 new papers in 30 daysSee all 629 papers on vasomotor symptoms
At a glance
A human study links vasomotor symptoms with ischemic stroke in postmenopausal women; another links them with greater brain white matter hyperintensity volume in women not using hormone therapy. Reviews link severe symptoms with epigenetic age. Human trials report symptom reductions with GS1-144 in postmenopausal women and a botanical neurokinin inhibitor, whereas a saffron trial in perimenopausal women shows no clear effect.
89 findings in 62 papers from 2005 to 2026, 26 of them since April 2026
“Women who developed VMS, compared to women who did not, had significantly higher median pre-estradiol suppression trunk/limb fat mass ratios (0.8 [0.7, 0.9] vs. 0.7 [0.6, 0.7], p = 0.01)”
- Human trial50
- Humans82
- Animals7
- In silico3
Interventions
27Hormone replacement therapy
downin humans10
10 studies
Hormone replacement therapy
downin humans10
Hormone replacement therapy decreases vasomotor symptoms in humans (eligible women after risk-reducing salpingo-oophorectomy).
“For eligible women, menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and prevents estrogen‐deficiency bone loss.”
Revieweligible women after risk-reducing salpingo-oophorectomyfemales
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
Hormone replacement therapy decreases vasomotor symptoms in humans (menopause).
“Menopausal hormone therapy remains the most effective treatment for vasomotor symptoms”
Reviewmenopause
Journal of clinical medicine
Hormone replacement therapy decreases vasomotor symptoms in humans (menopause).
“Hormone replacement therapy (HRT) remains the most effective treatment for vasomotor symptoms”
Reviewmenopausefemales
Hormone replacement therapy: an overview for South African pharmacists
SA pharmaceutical journal.
Hormone replacement therapy decreases vasomotor symptoms in humans (menopause).
“THM is the most effective treatment for vasomotor symptoms.”
Reviewmenopausefemales
Management of menopausal symptoms
FMC - Formación Médica Continuada en Atención Primaria
Hormone replacement therapy decreases vasomotor symptoms in humans (menopause) (efficacy exceeds eighty percent).
“The results demonstrate that efficacy in controlling vasomotor symptoms exceeds eighty percent.”
Reviewmenopausefemales
HORMONE THERAPY IN MENOPAUSE: EVALUATION OF BENEFITS AND RISKS
Asclepius International Journal of Scientific Health Science
Hormone replacement therapy decreases vasomotor symptoms in humans (menopause).
“MHT provides the most effective relief of vasomotor symptoms”
Reviewmenopausefemales
Menopausal Hormone Therapy-Risks, Benefits and Emerging Options: A Narrative Review
International journal of molecular sciences
Hormone replacement therapy decreases vasomotor symptoms in humans (menopause) (70%-90% reduction).
“Hormonal therapies (MHT/HRT), evolved from WHI trials, effectively reduce VMS by 70%-90%”
Reviewmenopausefemales
Frontiers in reproductive health
Hormone replacement therapy decreases vasomotor symptoms in humans (menopause).
“Menopausal hormonal therapy (MHT) is supported by level 1 evidence and can address many of the negative impacts associated with menopause, including VMS.”
Reviewmenopausefemales
Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms
Drugs
Hormone replacement therapy decreases vasomotor symptoms in humans (menopause transition).
“its value in the treatment of disabling vasomotor symptoms is still undisputed.”
Reviewmenopause transitionfemales
Hormone therapy and cardiovascular disease: Benefits and harms
Best practice & research. Clinical endocrinology & metabolism
Hormone replacement therapy decreases vasomotor symptoms in humans (menopause).
“Menopausal HT improves vasomotor symptoms and vulvovaginal atrophy symptoms and prevents osteoporosis-related fracture.”
Reviewmenopausefemales
Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
Elinzanetant
downin humans6downin reviews1
7 studies
Elinzanetant
downin humans6downin reviews1
Elinzanetant decreases vasomotor symptoms in humans (breast cancer-related vasomotor symptoms; compared with placebo) (SMD -0.51, 95% CI -0.95 to -0.07).
“elinzanetant (SMD -0.51, 95% CI -0.95 to -0.07)”
Reviewbreast cancer-related vasomotor symptoms; compared with placebofemales
Frontiers in pharmacology
Elinzanetant decreases vasomotor symptoms in humans (moderate to severe menopausal vasomotor symptoms).
“elinzanetant significantly reduced the frequency and severity of menopausal VMS (primary endpoints), with reductions in frequency evident as early as week 1”
Reviewmoderate to severe menopausal vasomotor symptomsoralup to 52 weeksfemales
Elinzanetant in moderate to severe menopausal vasomotor symptoms: a profile of its use
Drugs & Therapy Perspectives
Elinzanetant decreases vasomotor symptoms during and after menopause.
“A neurokinin inhibitor that can alleviate vasomotor symptoms during and after menopause.”
Reviewduring and after menopause
pharma-kritik
Elinzanetant decreases vasomotor symptoms in humans (associated with natural/surgical menopause or endocrine therapy for breast cancer).
“By week 12, all studies showed significant reductions vs. placebo, with benefits maintained for up to 50 weeks.”
Reviewassociated with natural/surgical menopause or endocrine therapy for breast cancerup to 50 weeksfemales
Maturitas
Elinzanetant decreases vasomotor symptoms in menopause (65.2%-67.0% reduction).
“elinzanetant achieved a 65.2%-67.0% reduction in VMS frequency by Week 12 (OASIS 1/2)”
Reviewin menopauseWeek 12
Journal of menopausal medicine
Elinzanetant decreases vasomotor symptoms in humans (moderate-to-severe vasomotor symptoms associated with menopause) (MD: -2.11, 95% CrI [-3.31, -0.92]).
“Elinzanetant significantly reduced daily VMS frequency versus PRX (MD: -2.11 [-3.31, -0.92])”
Reviewmoderate-to-severe vasomotor symptoms associated with menopause120 mgweek 12females
BJOG : an international journal of obstetrics and gynaecology
Elinzanetant decreases vasomotor symptoms in humans (postmenopausal women with moderate-to-severe vasomotor symptoms) (MD = -2.75, 95% CI: [-3.83, -1.67]).
“elinzanetant demonstrated a statistically significant difference in reducing both frequency and severity of VMSs at week 4 compared to placebo (MD = -2.75, 95% CI: [-3.83, -1.67], P < 0.00001”
Reviewpostmenopausal women with moderate-to-severe vasomotor symptomsweek 4femalesn = 1,699
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
Fezolinetant
downin humans6downin reviews1−60% vms
7 studies
Fezolinetant
downin humans6downin reviews1−60% vms
Fezolinetant decreases vasomotor symptoms in humans (postmenopausal women; compared with placebo) (60% to 70% reduction in VMS intensity).
“Fezolinetant was shown to be effective and safe in reducing the frequency and severity of vasomotor symptoms (VMS) compared with placebo in postmenopausal women.”
Reviewpostmenopausal women; compared with placebofemales
Universitas Médica
Fezolinetant decreases vasomotor symptoms (60% decrease in VMS).
“Non-hormonal Neurokini3 antagonists like fezolinetant, decreased VMS by 60% and benefited high-risk patients.”
Review
Innovative Drug Delivery Systems for Management of Menopausal Symptoms: A Systematic Review
International journal of women's health
Fezolinetant decreases vasomotor symptoms in humans (menopause) (50%-65% reduction).
“NK3R antagonists (fezolinetant, 50%-65% VMS reduction)”
Reviewmenopausefemales
Frontiers in reproductive health
Fezolinetant decreases vasomotor symptoms in humans (postmenopausal women).
“Emerging treatments like fezolinetant demonstrate promise in reducing VMS by addressing the underlying pathophysiology”
Reviewpostmenopausal womenfemales
Treatment of Menopausal Symptoms When Hormone Therapy Is Contraindicated
Seminars in reproductive medicine
Fezolinetant decreases vasomotor symptoms in humans (menopause).
“Fezolinetant has shown efficacy in reducing the frequency and severity of VMS”
Reviewmenopause
Expert opinion on drug metabolism & toxicology
Fezolinetant decreases vasomotor symptoms in menopausal women.
“NK3R antagonists provide a safe and effective treatment option for managing menopausal women with VMS.”
Reviewin menopausal women
European journal of obstetrics, gynecology, and reproductive biology
Fezolinetant decreases vasomotor symptoms in humans (associated with menopause; compared with placebo).
“Clinical trials have demonstrated fezolinetant is superior to placebo in decreasing the frequency and severity of vasomotor symptoms.”
Reviewassociated with menopause; compared with placebo
Fezolinetant: A New Nonhormonal Treatment for Vasomotor Symptoms
The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians
Hormone therapy
downin humans2
2 studies
Hormone therapy
downin humans2
Hormone therapy decreases vasomotor symptoms in humans (menopause).
“Hormone therapy remains the most effective treatment of vasomotor symptoms and genitourinary syndrome of menopause (GSM)”
Reviewmenopause
Hormone Therapy Considerations for Breast Cancer Survivors and High-Risk Women
Endocrinology and metabolism clinics of North America
Hormone therapy decreases vasomotor symptoms in humans (menopause).
“Hormone therapy is the most effective treatment of vasomotor symptoms”
Reviewmenopausefemales
The Medical clinics of North America
Neurokinin receptor antagonists
downin humans1
1 study
Neurokinin receptor antagonists
downin humans1
Neurokinin receptor antagonists decrease vasomotor symptoms in humans (menopause).
“Neurokinin receptor antagonists, particularly fezolinetant and elinzanetant, represent the most effective evidence-based non-hormonal pharmacologic therapies currently available.”
Reviewmenopausefemales
Non-hormonal management of menopause symptoms—the statement of the European Society of Gynecology
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
Stellate ganglion block
downin humans1
1 study
Stellate ganglion block
downin humans1
Stellate ganglion block decreases vasomotor symptoms in humans.
“The patient underwent an ultrasound-guided supraclavicular stellate ganglion block, resulting in a favorable clinical response that was sustained for six months.”
Human trialsevere hot flashes refractory to medical management in a patient with a history of breast cancer receiving tamoxifenultrasound-guided supraclavicularsix months
Interventional pain medicine
NK3 receptor antagonists
downin humans1
1 study
NK3 receptor antagonists
downin humans1
NK3 receptor antagonists decrease vasomotor symptoms in humans.
“NK3 antagonists significantly and rapidly reduced VMS frequency and severity versus placebo, with sustained efficacy up to 52 weeks.”
ReviewPerimenopausal or postmenopausal women with moderate-to-severe vasomotor symptoms; versus placeboUp to 52 weeksfemales
International Journal of Innovative Technologies in Social Science
Resistance training
downin humans1
1 study
Resistance training
downin humans1
Resistance training decreases vasomotor symptoms in humans (menopausal Korean women).
“incorporating resistance exercise into long-term exercise programs was necessary for alleviating vasomotor symptoms.”
Reviewmenopausal Korean womenlong-termfemales
The Asian Journal of Kinesiology
Escitalopram
downin humans1
1 study
Escitalopram
downin humans1
Escitalopram decreases vasomotor symptoms in humans (breast cancer-related vasomotor symptoms; compared with placebo) (SMD -1.08, 95% CI -1.80 to -0.37).
“Five interventions were significantly more effective than placebo: escitalopram (SMD -1.08, 95% CI -1.80 to -0.37)”
Reviewbreast cancer-related vasomotor symptoms; compared with placebofemales
Frontiers in pharmacology
Venlafaxine
downin humans1
1 study
Venlafaxine
downin humans1
Venlafaxine decreases vasomotor symptoms in humans (breast cancer-related vasomotor symptoms; compared with placebo) (SMD -0.42, 95% CI -0.76 to -0.07).
“venlafaxine 75 mg (SMD -0.42, 95% CI -0.76 to -0.07)”
Reviewbreast cancer-related vasomotor symptoms; compared with placebo75 mgfemales
Frontiers in pharmacology
Botanical neurokinin inhibitor
downin humans1
1 study
Botanical neurokinin inhibitor
downin humans1
Botanical neurokinin inhibitor decreases vasomotor symptoms in humans (-2.2 hot flashes per day (-47.7%) vs placebo, p = 0.003).
“BNI supplementation reduced VMS frequency by 2.2 hot flashes per day more than placebo (p = 0.003), corresponding to a 47.7% relative decrease.”
Human trial12 weeksn = 68
Maturitas
GS1-144
downin humans1
1 study
GS1-144
downin humans1
GS1-144 decreases vasomotor symptoms in humans (postmenopausal vasomotor symptoms) (-1.41 [-2.28 to -0.54]).
“VMS frequency was significantly reduced versus placebo for GS1-144 30 mg BID at week 4 (difference in change in least squares mean -1.31 [90% CI: -2.35 to -0.26], P =0.04) and week 12 (-1.41 [-2.28 to -0.54], P =0.008)”
Human trialpostmenopausal vasomotor symptoms30 mg BID12 weeksfemalesn = 276
GS1-144 reduced hot flashes in Chinese women after menopause
Menopause (New York, N.Y.)
Combined aerobic and resistance training
downin humans1
1 study
Combined aerobic and resistance training
downin humans1
Combined aerobic and resistance training decreases vasomotor symptoms in humans (postmenopausal women with moderate or severe VMS) (η2=0.81, p < 0.001).
“The exercise group showed a large improvement in VMS severity (MENQOL vasomotor domain, η2=0.81, p < 0.001)”
Human trialpostmenopausal women with moderate or severe VMS12 weeksfemalesn = 38
BMC women's health
Saffron
no changein humans1
1 study
Saffron
no changein humans1
Saffron showed no clear effect on vasomotor symptoms in perimenopausal women experiencing menopausal complaints.
“However, compared to the placebo, saffron was not associated with greater improvements in vasomotor symptoms, somatic symptoms, or other quality of life measures.”
Human trialin perimenopausal women experiencing menopausal complaintsaffron®14 mg twice daily12 weeksfemalesn = 82
Journal of menopausal medicine
All 27Fewer
Effects
7Quality of life
downin humans1no changein humans1
2 studies
Quality of life
downin humans1no changein humans1
Vasomotor symptoms were not clearly linked with quality of life in epithelial ovarian cancer survivors.
“VMS were not associated with poor global QoL, fatigue, insomnia or mood disorders.”
Humansin epithelial ovarian cancer survivorsfemalesn = 166
Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study
Gynecologic oncology
Vasomotor symptoms impair quality of life in humans.
“Severe vasomotor symptoms drive treatment seeking and can affect quality of life, mental health and work ability.”
Review
Risk factors, management and consequences of severe menopausal vasomotor symptoms
Nature reviews. Endocrinology
Nitric oxide–cGMP signaling
no changein humans1
1 study
Nitric oxide–cGMP signaling
no changein humans1
Vasomotor symptoms were not clearly linked with nitric oxide–cGMP signaling in humans (assessed by NG-nitro-L-arginine methyl ester perfusion during local heating).
“However, the NOS-mediated contribution did not differ between groups or across regions (all P > 0.15).”
Humansassessed by NG-nitro-L-arginine methyl ester perfusion during local heatingskinfemalesn = 18
Menopause (New York, N.Y.)
High frequency HRV
no changein humans1
1 study
High frequency HRV
no changein humans1
Vasomotor symptoms showed no clear effect on high frequency HRV in humans (peri- and/or post-menopause) (p = 0.11).
“There were no group differences in high frequency (HF) (p = 0.11).”
Reviewperi- and/or post-menopause
A systematic review of heart rate variability and menopausal vasomotor symptoms
Physiological reports
Low-frequency HRV
no changein humans1
1 study
Low-frequency HRV
no changein humans1
Vasomotor symptoms showed no clear effect on low-frequency HRV in humans (peri- and/or post-menopause) (Difference in means: 2.715 [95% CI: -0.124 to 5.555]; p = 0.06).
“The pooled analysis revealed no difference in low frequency (LF) in women with VMS compared to those without VMS (Difference in means: 2.715 [95% CI: -0.124 to 5.555]; p = 0.06).”
Reviewperi- and/or post-menopause
A systematic review of heart rate variability and menopausal vasomotor symptoms
Physiological reports
Cardiovascular and sympathetic responsiveness to cold pressor testing
no changein humans1
1 study
Cardiovascular and sympathetic responsiveness to cold pressor testing
no changein humans1
Vasomotor symptoms were not clearly linked with cardiovascular and sympathetic responsiveness to cold pressor testing in humans (Current or prior vasomotor symptoms compared with no history of vasomotor symptoms).
“HR, MAP, and MSNA responsiveness to CPT were not different between groups (P > 0.05).”
HumansCurrent or prior vasomotor symptoms compared with no history of vasomotor symptoms2-min cold pressor testfemales
Vasomotor symptoms of menopause, sympathetic activity, and blood pressure in postmenopausal females
American journal of physiology. Heart and circulatory physiology
Resting mean arterial pressure
no changein humans1
1 study
Resting mean arterial pressure
no changein humans1
Vasomotor symptoms were not clearly linked with resting mean arterial pressure in humans (Current or prior vasomotor symptoms compared with no history of vasomotor symptoms).
“there were no group differences in resting mean arterial pressure (MAP) or MSNA burst frequency (P > 0.05)”
HumansCurrent or prior vasomotor symptoms compared with no history of vasomotor symptomsfemales
Vasomotor symptoms of menopause, sympathetic activity, and blood pressure in postmenopausal females
American journal of physiology. Heart and circulatory physiology
Employment rates
no changein humans1
1 study
Employment rates
no changein humans1
Vasomotor symptoms were not clearly linked with employment rates in humans (menopause).
“Vasomotor symptoms tend not to be associated with lower employment rates”
Humansmenopausefemales
The consequences of early menopause and menopause symptoms for labour market participation
Social science & medicine (1982)
Upstream
1TACR3
no changein humans1
1 study
TACR3
no changein humans1
TACR3 was not clearly linked with vasomotor symptoms in humans (rare variant predicted to reduce functional NK3R levels) (P = 0.6).
“rare variant predicted to reduce functional NK3R levels that was associated with later menarche (P = 5 × 10−9) but showed no association with VMS (P = 0.6)”
Humansrare variant predicted to reduce functional NK3R levelsfemales
BMC medical genomics
Associations
28Cardiovascular disease
upin humans2
2 studies
Cardiovascular disease
upin humans2
Vasomotor symptoms are associated with cardiovascular disease in humans (perimenopause).
“vasomotor symptoms and sleep disturbance are associated with adverse cardiometabolic profiles and increased cardiovascular disease risk.”
Reviewperimenopause
Climacteric : the journal of the International Menopause Society
Vasomotor symptoms are associated with cardiovascular disease in humans.
“We review the incidence, management and potential long-term health consequences of severe vasomotor symptoms, including cardiovascular disease, diabetes mellitus, cognitive dysfunction, bone health and quality of life.”
Review
Risk factors, management and consequences of severe menopausal vasomotor symptoms
Nature reviews. Endocrinology
Quality of life
downin humans2
2 studies
Quality of life
downin humans2
Vasomotor symptoms are associated with quality of life in humans (Canadian perimenopausal and postmenopausal women with moderate/severe vasomotor symptoms) (Mean total Menopause-Specific Quality of Life questionnaire score: 4.3/8).
“were associated with impairment in quality of life, work productivity, daily activities, and sleep in perimenopausal and postmenopausal women.”
HumansCanadian perimenopausal and postmenopausal women with moderate/severe vasomotor symptomsfemalesn = 400
Menopause (New York, N.Y.)
Vasomotor symptoms are associated with quality of life in humans (Perimenopausal and postmenopausal women with moderate to severe vasomotor symptoms).
“showed that VMS affected quality of life across all domains measured”
HumansPerimenopausal and postmenopausal women with moderate to severe vasomotor symptomsfemalesn = 2,176
Menopause (New York, N.Y.)
Ischemic stroke
upin humans1OR 2.16
1 study
Ischemic stroke
upin humans1OR 2.16
Vasomotor symptoms predict ischemic stroke in humans (Postmenopausal women; perimenopausal and recent hot flashes) (AUC 0.809).
“The area under the ROC curve for perimenopausal and recent hot flashes was 0.809 (p < 0.001), indicating substantial predictive value.”
HumansPostmenopausal women; perimenopausal and recent hot flashesfemalesn = 358
Association Between Vasomotor Symptoms and Ischemic Stroke: A Case-Control Study
Brain and behavior
Vasomotor symptoms are associated with ischemic stroke in humans (Postmenopausal women; perimenopausal vasomotor symptoms; multivariable adjustment) (OR 2.16, 95% CI 1.42–3.30).
“both perimenopausal VMS (OR: 2.16, 95% CI: 1.42-3.30, p < 0.001) and the past week VMS (OR: 2.06, 95% CI: 1.33-3.26, p = 0.001) remained independently associated with IS.”
HumansPostmenopausal women; perimenopausal vasomotor symptoms; multivariable adjustmentfemalesn = 358
Association Between Vasomotor Symptoms and Ischemic Stroke: A Case-Control Study
Brain and behavior
Premenstrual disorders
upin humans1
1 study
Premenstrual disorders
upin humans1
Premenstrual disorders are associated with vasomotor symptoms in humans (Age-standardized comparison with women without a history of premenstrual disorders).
“higher prevalences of hypertension (p=0.006) and a history of VMS (p<0.001) relative to women without PMDs.”
HumansAge-standardized comparison with women without a history of premenstrual disordersfemalesn = 4,405
Premenstrual disorders were not linked to midlife artery disease
ESC Congress 2026 abstract
Perinatal depression
upin humans1
1 study
Perinatal depression
upin humans1
Perinatal depression is associated with vasomotor symptoms in humans (adjusted for age, race/ethnicity, education, parity, BMI, and smoking status) (ARR 1.14, 95% CI 1.00, 1.30).
“Women with perinatal depression were more likely to report vasomotor symptoms (44.1%) during midlife than those without perinatal depression (38.1%; ARR 1.14, 95% CI 1.00, 1.30).”
Humansadjusted for age, race/ethnicity, education, parity, BMI, and smoking status12-14 years after index birthfemalesn = 1,479
Maturitas
Cutaneous vascular conductance
upin humans1
1 study
Cutaneous vascular conductance
upin humans1
Vasomotor symptoms are associated with cutaneous vascular conductance in humans during 42 °C local heating (7.2 [1.7, 23.5]%).
“During the 42 °C heating plateau, females with VMS exhibited greater %CVCmax than those without VMS when responses were pooled across regions (7.2 [1.7, 23.5]%; P = 0.013)”
Humansduring 42 °C local heatingskinfemalesn = 18
Menopause (New York, N.Y.)
Epigenetic age
upin humans1
1 study
Epigenetic age
upin humans1
Vasomotor symptoms are associated with epigenetic age in humans (Severe vasomotor symptoms).
“severe vasomotor symptoms have been linked to higher epigenetic age”
ReviewSevere vasomotor symptomsfemales
Biological markers of aging across the menopause transition: current evidence
Menopause (New York, N.Y.)
Frequent mood changes
upin humans1
1 study
Frequent mood changes
upin humans1
Vasomotor symptoms are associated with frequent mood changes in humans (~50%-60% increased odds).
“VMS and frequent mood changes were associated with ~50%-60% increased odds of the other”
Humansn = 2,066
Menopause (New York, N.Y.)
Sleep disturbance
upin humans1
1 study
Sleep disturbance
upin humans1
Vasomotor symptoms are associated with sleep disturbance in humans (double the odds).
“VMS and sleep disturbances were each associated with double the odds of the other”
Humansn = 2,066
Menopause (New York, N.Y.)
Worsening depressive symptoms
upin humans1OR 2.95
1 study
Worsening depressive symptoms
upin humans1OR 2.95
Vasomotor symptoms are associated with worsening depressive symptoms in humans (Korean women during menopausal transition) (OR 2.95, 95% CI 1.30 to 6.70).
“moderate-to-severe vasomotor symptoms (OR 2.95, 95% CI 1.30 to 6.70) were significantly associated with the worsening trajectory.”
HumansKorean women during menopausal transitionfemales
Epidemiology and psychiatric sciences
HDL
downin humans1
1 study
HDL
downin humans1
HDL is associated with vasomotor symptoms in humans (before GnRH agonist-induced estradiol suppression) (median 53 vs 70 mg/dl).
“significantly lower median HDL (53 mg/dl [47, 59] vs. 70 mg/dl [62, 73], p = 0.001)”
Human trialbefore GnRH agonist-induced estradiol suppressionfemales
ENDO 2025 abstract
Trunk/limb fat mass ratio
upin humans1
1 study
Trunk/limb fat mass ratio
upin humans1
Trunk/limb fat mass ratio is associated with vasomotor symptoms in humans (before GnRH agonist-induced estradiol suppression) (median 0.8 [0.7, 0.9] vs 0.7 [0.6, 0.7]).
“Women who developed VMS, compared to women who did not, had significantly higher median pre-estradiol suppression trunk/limb fat mass ratios (0.8 [0.7, 0.9] vs. 0.7 [0.6, 0.7], p = 0.01)”
Human trialbefore GnRH agonist-induced estradiol suppressionfemales
ENDO 2025 abstract
All 28Fewer
Trial sponsors
Company2 trialsPhase 4244 people
Company3 trialsPhase 31,074 people
Company2 trialsPhase 32,585 people
Company1 trialPhase 3453 people
Company1 trialPhase 3238 people
Company1 trialPhase 2150 people
Company1 trialPhase 2139 people
Company1 trialPhase 2120 people
Funding
14 grants since 2018National Institute on Aging$8.4MNational Heart, Lung, and Blood Institute$2.4MMassachusetts General Hospital$595K
National Heart, Lung, and Blood InstituteAlbert Einstein College of Medicine$865K2026–2031
Menopause-related Vasomotor Symptoms and Cardiovascular Health
National Heart, Lung, and Blood InstituteMassachusetts General Hospital$739K2025–2030
Menopausal Vasomotor Symptoms and Brain Aging in Women (sub-award to UNIVERSITY OF ILLINOIS)
University of PittsburghUniversity of Illinois Urbana-Champaign$83.7K2025
Massachusetts General HospitalBrigham and Women's Hospital$381K2025
Menopausal Vasomotor Symptoms and Brain Aging in Women
National Institute on AgingUniversity of Pittsburgh at Pittsburgh$760K2016–2027
American Heart Association2025–2027
Swiss National Science FoundationUniversity of BernCHF 4.9K2025
National Institute on AgingUniversity of Illinois Chicago$52.1K2024–2025
Vasomotor symptoms of menopause and cardiovascular disease: What is the link?
National Institute on AgingUniversity of Minnesota$193K2023–2026
How this record changed
Summary written from the findings.